here debug-> :lcxx94

PharmaceuticalInvesting News

Your trusted source for investing success


Pharmaceutical Companies – Top Performers in Terms of Net Profit

Before investing, get our FREE Special Report, Pharmaceutical Investing Principles And Pharmaceutical Stocks To Buy 2017.

Dear Pharmaceutical Investor,

That’s right, pharmaceutical companies have the highest profit margins across the main industrial sectors, beating out banks, carmakers, media and even oil and gas. According to a Forbes report, in 2013 the pharmaceutical industry had an average profit margin of nearly 20 percent, with American pharmaceutical giant Pfizer (NYSE:PFE) achieving an incredible profit margin of 42 percent.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) estimates that approximately 12 or 13 years may elapse between the first synthesis of an active substance and its introduction to the market. And, the EFPIA estimates that only one or two out of every 10,000 substances synthesized in laboratories will ever pass all stages of development to become marketable medicines. Those are slim chances, and it’s important to note that even reaching marketability doesn’t guarantee a drug’s profitability. In fact, research from PhRMA shows that on average, only two in 10 drugs are profitable.

With odds like that, how does an investor know where to put their hard earned money?

Start with this FREE Special Report: Pharmaceutical Investing Principles And Pharmaceutical Stocks To Buy 2017. Download it now!

This free report is intended to help you…

  • Educate yourself on what is happening with the pharmaceuticals market and the companies in it
  • Consider the different markets within pharmaceuticals and which you think will do best
  • Understand what stages pharmaceutical companies go through and when there is the biggest risk – and the biggest reward
  • Evaluate the experts’ opinions and forecasts for yourself before making any investments
  • Gain expertise in pharmaceutical investing
  • Confidently make buying and selling decisions all year long, whenever you see an opportunity
  • Profit from improving people’s health while helping companies build their success

There is a lot of information in the news about healthcare and pharmaceutical companies. But how much about investing in those companies? There is some, but that information usually focuses on the big names – names the investors already know about.

There are hundreds of pharmaceutical companies that represent different types of investment opportunities. We have provided you with a great place to start.

Why you should read Pharmaceutical Investing Principles And Pharmaceutical Stocks To Buy 2017

Pharmaceutical Investing News is part of Investing News Network, a growing network of authoritative publications delivering independent, unbiased news and education for investors. We deliver knowledgeable, carefully curated coverage of a variety of markets including pharmaceuticals, biotech, medical devices and many others. This means you read nothing but the best from the entire world of investing advice, and never have to waste your valuable time doing hours, days or weeks of research yourself.

At the same time, not a single word of the content we choose for you is paid for by Pfizer or Merck or any company or investment advisor: We choose our content based solely on its informational and educational value to you, the investor.

I’m sure you can see the value of such investing intelligence. And we have carefully selected unbiased, independent articles to put into this FREE Special Report, Investing in Pharmaceutical Companies: Pharmaceutical News, and Top Pharmaceutical Stocks to Buy.

We created this special report because there is so much to know about investing in pharmaceutical companies such as Pfizer that we wanted to make it easy for you to get started. And as for why we would give away such valuable advice, the answer is simple: It’s the best way we know to introduce ourselves and get this information into the hands of as many investors as possible.

Of course, investing in pharmaceutical companies isn’t for everyone. When you read this free report, you’ll learn one of the cardinal rules: Have patience. You’ll learn to distinguish between the pessimists who only consider short-term investing and those experts who take the long view – a view that could turn out to be very profitable indeed.

So if you want to invest in a way that takes advantage of one of the most powerful mega-trends our generation — or any generation — will ever see…

If you believe your hard earned investment dollars should go to companies that are dedicated to improving the lives of others…

If you want to learn how to evaluate pharmaceutical companies before they are in the headlines…

Start today with this free special report. Right now.

After all, a lot of people know that investing in healthcare has significant upside potential. Aging populations in the most wealthy countries will be spending trillions on their health and trying to maintain a healthy lifestyle. If you’re the kind of person who likes to identify new products and trends to improve your investing results — to find the companies to invest in before everyone else — then you shouldn’t wait to start reading this Special Report.

The range of different types of healthcare companies to invest in is vast. Are you looking for companies that are trying to cure cancer? Or companies that help those with Alzheimer’s? What about companies trying to help deal with the deadly Ebola outbreak in West Africa?

This Special Report is a great place to start. Investing in Pharmaceutical Companies: Pharmaceutical News, and Top Pharmaceutical Stocks to Buy touches on all of these topics and more. And if you’re interested in what the experts are saying, we provide links to reports from the World Health Organization, the Pharmaceutical Research and Manufacturers of America, Forbes and the BBC. Just to name a few!

Changing demographics of the US are contributing to the popularity of healthcare ETFs. Baby boomers, those born between the years 1946 and 1964, represent approximately one-quarter of the US population, according to the Population Reference Bureau. More importantly, as this generation continues to age, it will result in much more spending in the healthcare sector, from prescription drugs to hospital care.

This is not the kind of opportunity that comes twice. Don’t wait to start reading this Special Report.

What you will learn when you read Investing in Pharmaceutical Companies: Pharmaceutical News, and Top Pharmaceutical Stocks to Buy

For those still hesitant about investing in pharmaceutical stocks, it’s worth noting that according to EY’s “Firepower and Growth Gap Report 2015,” between 2009 and 2014, shareholders of big pharmaceutical companies saw their returns increase by 116 percent. That made the sector one of the safest and most stable to invest in, despite the recent economic downturn.

Learn about one interesting pharmaceutical industry trend is the movement away from animal testing and towards cheaper and more efficient testing technology. LiverChip is one such technology. The company Benitec Biopharma (ASX:BLT) is using LiverChip to search for a potential cure for hepatitis B.

Or what about personalized medicine — sometimes referred to as precision medicine. It is the idea of providing tailored medical care according to a patient’s individual characteristics, needs, preferences and genetic makeup. Large pharmaceutical companies have started looking at this seriously and have been gradually moving away from the research and development of blockbuster drugs in favor of an increased focus on targeted therapies.

In all, there simply is no other single resource that brings together the best current information on pharmaceutical investing, whether you’re a novice healthcare investor or an old hand. This free Special Report, Pharmaceutical Investing Principles And Pharmaceutical Stocks To Buy 2017, is, if you’ll pardon the pun, just what the doctor ordered! Download it today!

And at this price – $0.00 – it’s certainly affordable! Don’t waste another minute wondering how what company is going to be the next Ariad Pharmaceuticals and Pharmacyte, or in trying to sift through the onslaught of information – some of it valuable, much of it not – on your own. Read our Special Report today, and start making savvy investing decisions tomorrow!

We’re pleased to be able to make it available to you at no cost, and hope you’ll take advantage of the expertise it delivers.

Yours for profitable, healthy investing,

Nick Smith
Publisher & CEO
Investing News Network

PS: Did I mention that this Special Report also includes numerous links to additional insight – information you might never find on your own? This is the kind of guidance that’s a deal at any price — but especially when it’s FREE. Download it today!

PPS: Here at Pharmaceutical Investing News, we have no hidden, vested interest in getting you to invest in pharmaceutical companies. We simply believe investors like you deserve the best professional guidance available, and we just happen to deliver it for free in this Special Report. Read it now!

*Your free Pharmaceutical Investor Kits include:

  • DelMar Pharmaceuticals
  • Q BioMed
  • RespireRx Pharmaceuticals
  • 3D Signatures



Leave a Reply

Enter Your Log In Credentials

Privacy & Legal Policy

This website is part of the Investing News Network published by Dig Media Inc.


INN's mission is to be the world's number one source of independent, unbiased news and education helping investors realized their financial goals. We also strive to be internationally respected for our integrity, our people and our commitment to excellence. Therefore, we are very concerned with the privacy rights of our audience and are committed to protecting the information collected about you.We have taken extensive measures to protect the confidentiality of your personal information and to protect your data from misuse and unauthorized access or disclosure. Unfortunately, no data transmission over the Internet can be guaranteed to be 100% secure. As a result, Dig Media cannot ensure or warrant the security of the information you transmit to us and you do so at your own risk.

Contact Information

Our postal address is

L200 - 560 Beatty Street,

Vancouver, BC V6B 2L3

We can be reached via e-mail at or telephone at +1-604-688-8231

Information Collected

For each visitor to our website, our web server automatically recognizes no information regarding the domain or e-mail address.

We collect information volunteered by the visitor, such as survey information and/or site registrations, name and address, telephone number.

The information we collect is used to notify visitors about updates to our website, shared with other reputable organizations to help them contact visitors for marketing purposes.

With respect to cookies: When you visit our websites, we send one or more cookies, a small file containing a string of characters, to your computer that uniquely identifies your browser during your visit. We use these cookies to maintain your connection as you move from page to page, and to ensure anything you submit, such as a comment or a form, is not rejected. You can reset your browser to refuse all cookies or to indicate when a cookie is being sent. However, some website features or services may not function properly without cookies.

If you do not want to receive e-mail from us in the future, please let us know by sending us e-mail at the above address.

Persons who supply us with their telephone numbers on-line may receive telephone contact from us with information regarding new products and services or upcoming events. If you do not wish to receive such telephone calls, please let us know by sending us e-mail at the above address.

Ad Server

With respect to Ad Servers:

Other third-party companies which place advertising on our site may collect information about you when you view or click on their advertising through the use of their cookies or other tracking technologies, which may include delivering targeted advertisements and marketing messages based upon the third party websites that you visit, or other purposes. We cannot control this collection of information and are not responsible for the privacy policies and data collection, use and disclosure practices of these third party advertisers. You should contact these third party advertisers directly if you have any questions about their use of the information that they collect from you. Google-DoubleClick DFP is our third party ad server. If you would like to know more about their information gathering practices and opt-out procedures, please see Google ad policies.

Also, if you would like more information about this practice and to know your choices about not having this information used by these companies, please see NAI Opt-out Options.

Information Use

We only share personal information with other companies or individuals outside of the cases outlined above in the following limited circumstances:

We may share with third parties certain pieces of aggregated, non-personal information, such as the number of users who searched for a particular term, for example, or how many users clicked on a particular advertisement. Such information does not identify you individually.


We may remarket your information. Remarketing is a way for us to connect with users, based upon your past interactions with INN websites. Third-party marketing vendors may be hired by INN to perform remarketing services. As a result, third-party vendors, including Google, may show INN ads on sites on the internet. Third-party vendors, including Google, use cookies to serve ads based on a user's prior visits to INN websites.

To opt out of customized Google Display Network ads click here. To find out more about how Google uses any data it collects please visit
Any information collected is used only for remarketing purposes and will not be used by them for any other purpose.

Future Use

From time to time, we may use visitor information for new, unanticipated uses not previously disclosed in our privacy notice. If our information practices change at some time in the future we will post the policy changes to our website to notify you of these changes and provide you with the ability to opt out of these new uses. If you are concerned about how your information is used, you should check back at our website periodically.

Accessing Your Data

Please contact us at the address above for any additional questions about the management or use of personal data.

Upon request we provide site visitors with access to communications that the visitor has directed to our site (e.g., e-mails, customer inquiries), contact information (e.g., name, address, phone number) that we maintain about them.

Visitors can access this information by e-mailing us at the above address.

Upon request we offer visitors the ability to have inaccuracies corrected in contact information.

Visitors can have this information corrected by sending us e-mail at the above address.


With respect to security: We have appropriate security measures in place in our physical facilities to protect against the loss, misuse or alteration of information that we have collected from you at our site.

Your Acceptance of These Terms

By using this site, or by submitting personal information to us, you signify your agreement to Dig Media's Privacy Policy and Terms of Use. From time to time we may change or update our piracy policies. It is your responsibility to check back regularly to inform yourself of such changes. Your continued use of this or any Dig Media website following the posting of changes to these terms will be deemed as your acceptance of those changes.

The foregoing policies are in effect as of August 1, 2012. Dig media reserves the right to change this policy statement at any time by posting the revised policy to this website. This statement and the policies outlined herein are not intended to and do not create any contractual or other legal rights in or on behalf of any party.

If you feel that this site is not following its stated information policy, you may contact us at the above addresses or phone number.

Investing News Network